Credit Suisse Initiates Coverage on Pfizer (PFE)
Equities researchers at Credit Suisse initiated coverage on shares of Pfizer (NYSE:PFE) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on PFE. Analysts at JPMorgan Chase & Co. raised their price target on shares of Pfizer from $33.00 to $34.00 in a research note to investors on Friday, September 27th. They now have an “overweight” rating on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Pfizer from $31.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Pfizer to $28.50 in a research note to investors on Tuesday, September 3rd. They now have a “market perform” rating on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $30.53.
Shares of Pfizer (NYSE:PFE) traded down 1.33% during mid-day trading on Tuesday, hitting $28.24. 24,954,036 shares of the company’s stock traded hands. Pfizer has a 52-week low of $23.55 and a 52-week high of $31.15. The stock has a 50-day moving average of $28.50 and a 200-day moving average of $28.88. The company has a market cap of $187.0 billion and a P/E ratio of 7.94.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was down 7.1% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.16 earnings per share for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.